Spanish reimbursement for CSL’s Hemgenix

CSL Behring, a part of Australia's CSL Ltd (ASX: CSL),  has been granted a positive recommendation by the Spanish Interministerial Commission on the Pricing of Medicines (CIPM), resulting in national reimbursement for Hemgenix (etranacogene dezaparvovec) for eligible haemophilia B patients in Spain.

Hemgenix is the first one-time gene therapy approved in Spain for adults with severe and moderately severe aemophilia B (congenital Factor IX deficiency) without a history of Factor IX (FIX) inhibitors.

CSL Behring has described this new option as a paradigm shift, and a transformative approach to hemophilia B management by offering a durable alternative to frequent intravenous Factor IX infusions, which can significantly impact the quality of life and wellbeing of patients.